SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (265)10/5/2005 11:17:01 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 447
 
So far, total Rx trend does not indicate significant LONGER use of Terceva versus Iressa (before debacle). How much Tarceva penetrated second line treatment, is real thing for future projection (as for this indication one will expect longer treatment duration).

Miljenko